Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease

Inclusion Criteria

• •18 years or older at time of entry on study
• •Disease extent confirmed and documented by CT scan within 45 days of entry on study
• •normal glucose 6-phosphate dehydrogenase
• •no current calcium oxalate nephrolithiasis with the potential to reduce urinary flow
• •ability to understand the informed consent process and to give informed consent to treatment
• •measurable solid tumor neoplastic disease (using RECIST criteria)
• •life expectancy greater than 8-weeks
• •will agree to undergo central line placement (examples are: port-a-catheter, central venous catheter, percutaneously inserted central catheter \[PICC\] line placement). Patient or regular caregiver must be able to maintain flush central line as directed by study physician. (Study center will provide periodic site dressing changes as required)
• •Failed curative therapy or patient ineligible for definitive curative therapy
• •Karnofsky performance status of at least 40